Astellas Pharma (OTCMKTS:ALPMY) Downgraded to Hold Rating by Zacks Research

Zacks Research downgraded shares of Astellas Pharma (OTCMKTS:ALPMY) from a strong-buy rating to a hold rating in a report released on Monday,Zacks.com reports.

A number of other research analysts also recently weighed in on the company. Smbc Nikko Sec. raised Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. Jefferies Financial Group raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Astellas Pharma Stock Down 2.0%

Shares of ALPMY stock opened at $13.93 on Monday. The stock’s 50 day simple moving average is $15.35 and its 200 day simple moving average is $14.48. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.84 and a current ratio of 1.09. Astellas Pharma has a twelve month low of $9.11 and a twelve month high of $17.35. The company has a market capitalization of $25.21 billion, a price-to-earnings ratio of 12.97 and a beta of 0.08.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings data on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%.The business had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.28 billion. As a group, research analysts predict that Astellas Pharma will post 1.29 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).